Material solutions for delivery of CRISPR/Cas-based genome editing tools: Current status and future outlook

Abstract Clustered regularly interspaced short palindromic repeat (CRISPR)/associated protein (CRISPR/Cas) system is an adaptable immune mechanism used by many bacteria to protect themselves from invading nucleic acids, and it has been recently exploited as an efficient tool for site-specific, programmable genome editing in both single cells and whole organisms with a precise manner. CRISPR/Cas system has been shown its great potentials for a wide range of biomedical applications, such as transcriptional control, epigenetic modification, genome-wide screening and chromosomal imaging, and treatment of genetic disorders. Despite these excitements, the shortage of delivery materials that can deliver genome editing tools (including plasmid DNA, mRNA, and ribonucleoprotein) represents one of the major challenges for successful CRISPR/Cas-based genome editing. This review seeks to provide a comprehensive overview of different types of carriers ranging from classic drug delivery materials to advanced drug delivery systems that can transport CRISPR/Cas systems and mediate genome editing at the targeted loci. The challenges and future prospects of the delivery materials for optimizing the CRISPR delivery system for clinical translations are also highlighted.

[1]  E. Andersen,et al.  Prospects and challenges of CRISPR/Cas genome editing for the study and control of neglected vector‐borne nematode diseases , 2016, The FEBS journal.

[2]  Lukas E Dow,et al.  Inducible in vivo genome editing with CRISPR/Cas9 , 2015, Nature Biotechnology.

[3]  Xuesi Chen,et al.  Polymeric Nanocarriers for Drug Delivery in Osteosarcoma Treatment. , 2015, Current pharmaceutical design.

[4]  Eric M. Walters,et al.  Use of the CRISPR/Cas9 System to Produce Genetically Engineered Pigs from In Vitro-Derived Oocytes and Embryos1 , 2014, Biology of reproduction.

[5]  Jean-Paul Concordet,et al.  Highly efficient CRISPR/Cas9-mediated knock-in in zebrafish by homology-independent DNA repair , 2014, Genome research.

[6]  H. Kuh,et al.  Improving drug delivery to solid tumors: priming the tumor microenvironment. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[7]  Wei Tang,et al.  Correction of a genetic disease in mouse via use of CRISPR-Cas9. , 2013, Cell stem cell.

[8]  J. Joung,et al.  Defining and improving the genome-wide specificities of CRISPR–Cas9 nucleases , 2016, Nature Reviews Genetics.

[9]  A. Hatefi,et al.  Development of recombinant cationic polymers for gene therapy research. , 2010, Advanced drug delivery reviews.

[10]  S. Akira,et al.  A Toll-like receptor recognizes bacterial DNA , 2000, Nature.

[11]  Di Huang,et al.  Overcoming ocular drug delivery barriers through the use of physical forces , 2017, Advanced drug delivery reviews.

[12]  Hojun Li,et al.  In vivo genome editing restores hemostasis in a mouse model of hemophilia , 2011, Nature.

[13]  Jihwan Son,et al.  Optimized phospholipid-based nanoparticles for inner ear drug delivery and therapy. , 2018, Biomaterials.

[14]  M. Carreon,et al.  Highly permeable zeolite imidazolate framework-8 membranes for CO2/CH4 separation. , 2010, Journal of the American Chemical Society.

[15]  Lei Wang,et al.  Generation of Gene-Modified Cynomolgus Monkey via Cas9/RNA-Mediated Gene Targeting in One-Cell Embryos , 2014, Cell.

[16]  Boris Fehse,et al.  Efficient gene editing via non-viral delivery of CRISPR-Cas9 system using polymeric and hybrid microcarriers. , 2018, Nanomedicine : nanotechnology, biology, and medicine.

[17]  Hans Clevers,et al.  Sequential cancer mutations in cultured human intestinal stem cells , 2015, Nature.

[18]  Yi-Wei Lee,et al.  Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing. , 2017, ACS nano.

[19]  Philippe Horvath,et al.  The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA , 2010, Nature.

[20]  Daniel G. Anderson,et al.  Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing , 2017, Nature Biotechnology.

[21]  R. Ruoff,et al.  The chemistry of graphene oxide. , 2010, Chemical Society reviews.

[22]  Konstantin Severinov,et al.  CRISPR immunity relies on the consecutive binding and degradation of negatively supercoiled invader DNA by Cascade and Cas3. , 2012, Molecular cell.

[23]  Robert Langer,et al.  Partial DNA-guided Cas9 enables genome editing with reduced off-target activity. , 2018, Nature chemical biology.

[24]  Shana O Kelley,et al.  Recent advances in the use of cell-penetrating peptides for medical and biological applications. , 2009, Advanced drug delivery reviews.

[25]  Yasuhiko Tabata,et al.  Dual-controlled release system of drugs for bone regeneration. , 2015, Advanced drug delivery reviews.

[26]  Yi-Wei Lee,et al.  In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges. , 2017, Bioconjugate chemistry.

[27]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[28]  Gandhi Rádis-Baptista,et al.  Cell-penetrating peptides (CPPs): From delivery of nucleic acids and antigens to transduction of engineered nucleases for application in transgenesis. , 2017, Journal of biotechnology.

[29]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[30]  Chankyu Park,et al.  Nonviral Genome Editing Based on a Polymer-Derivatized CRISPR Nanocomplex for Targeting Bacterial Pathogens and Antibiotic Resistance. , 2017, Bioconjugate chemistry.

[31]  A. Mitra,et al.  Evaluation of an Ex Vivo Model Implication for Carrier-Mediated Retinal Drug Delivery , 2006, Current eye research.

[32]  D. Wells,et al.  Gene Therapy Progress and Prospects: Electroporation and other physical methods , 2004, Gene Therapy.

[33]  Fajr A. Aleisa,et al.  Endosomal Escape and Delivery of CRISPR/Cas9 Genome Editing Machinery Enabled by Nanoscale Zeolitic Imidazolate Framework. , 2018, Journal of the American Chemical Society.

[34]  Kai Yang,et al.  Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy. , 2010, Nano letters.

[35]  Vítor M Gaspar,et al.  Stimuli‐responsive nanocarriers for delivery of bone therapeutics – Barriers and progresses , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[36]  Yang Yang,et al.  A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice , 2016, Nature Biotechnology.

[37]  Hakho Lee,et al.  Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis , 2015, Cell.

[38]  Aviv Regev,et al.  Nucleic acid detection with CRISPR-Cas13a/C2c2 , 2017, Science.

[39]  Seung Min Kim,et al.  Simple in Vivo Gene Editing via Direct Self-Assembly of Cas9 Ribonucleoprotein Complexes for Cancer Treatment. , 2018, ACS nano.

[40]  Kevin S. Li,et al.  Inner ear drug delivery: Recent advances, challenges, and perspective , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[41]  Qiaobing Xu,et al.  Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents , 2017, Nature.

[42]  M. Lotze,et al.  Good things come in small packages: exosomes, immunity and cancer , 2014, Cancer Gene Therapy.

[43]  Leaf Huang,et al.  Non-viral is superior to viral gene delivery. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[44]  Hao Zhu,et al.  Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA. , 2017, Angewandte Chemie.

[45]  E. Lander,et al.  Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.

[46]  Fyodor D Urnov,et al.  In vivo cleavage of transgene donors promotes nuclease‐mediated targeted integration , 2013, Biotechnology and bioengineering.

[47]  Jiu-lin Du,et al.  Intron targeting-mediated and endogenous gene integrity-maintaining knockin in zebrafish using the CRISPR/Cas9 system , 2015, Cell Research.

[48]  Xiurui Zhu,et al.  A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo , 2017, Cell Research.

[49]  Yong-Hee Kim,et al.  Current and future delivery systems for engineered nucleases: ZFN, TALEN and RGEN. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[50]  Peter C. Fineran,et al.  Memory of viral infections by CRISPR-Cas adaptive immune systems: acquisition of new information. , 2012, Virology.

[51]  Chao Wang,et al.  Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. , 2015, Angewandte Chemie.

[52]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[53]  Mehrdad Hamidi,et al.  Hydrogel nanoparticles in drug delivery. , 2008, Advanced drug delivery reviews.

[54]  Yann Nguyen,et al.  Recent advances in local drug delivery to the inner ear. , 2015, International journal of pharmaceutics.

[55]  Mark M. Banaszak Holl,et al.  Multivalent Polymers for Drug Delivery and Imaging: The Challenges of Conjugation , 2014, Biomacromolecules.

[56]  Charles A Gersbach,et al.  Enabling functional genomics with genome engineering , 2015, Genome research.

[57]  E. Olson,et al.  Prevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA , 2014, Science.

[58]  David R. Liu,et al.  Discovery and characterization of a peptide that enhances endosomal escape of delivered proteins in vitro and in vivo. , 2015, Journal of the American Chemical Society.

[59]  Edward M. Callaway,et al.  In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration , 2016, Nature.

[60]  D. Rossi,et al.  Cell-Penetrating Peptides: From Basic Research to Clinics. , 2017, Trends in pharmacological sciences.

[61]  Ning Wang,et al.  Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice. , 2017, ACS nano.

[62]  Kinam Park,et al.  Hydrogels for delivery of bioactive agents: a historical perspective. , 2013, Advanced drug delivery reviews.

[63]  Jennifer A. Doudna,et al.  Enhanced proofreading governs CRISPR-Cas9 targeting accuracy , 2017, Nature.

[64]  Amilcar Tanuri,et al.  Comparison of the editing patterns and editing efficiencies of TALEN and CRISPR-Cas9 when targeting the human CCR5 gene , 2018, Genetics and molecular biology.

[65]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[66]  J. Keith Joung,et al.  Efficient Delivery of Genome-Editing Proteins In Vitro and In Vivo , 2014, Nature Biotechnology.

[67]  Liza J. Raggatt,et al.  Cellular and Molecular Mechanisms of Bone Remodeling* , 2010, The Journal of Biological Chemistry.

[68]  Daesik Kim,et al.  Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins , 2014, Genome research.

[69]  Randall J. Platt,et al.  Therapeutic genome editing: prospects and challenges , 2015, Nature Medicine.

[70]  Kaihong Zhou,et al.  Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing. , 2018, Journal of the American Chemical Society.

[71]  H. Dai,et al.  Chemically Derived, Ultrasmooth Graphene Nanoribbon Semiconductors , 2008, Science.

[72]  Marcello Maresca,et al.  Obligate Ligation-Gated Recombination (ObLiGaRe): Custom-designed nuclease-mediated targeted integration through nonhomologous end joining , 2013, Genome research.

[73]  Tetsushi Sakuma,et al.  MMEJ-assisted gene knock-in using TALENs and CRISPR-Cas9 with the PITCh systems , 2015, Nature Protocols.

[74]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[75]  Andrea M Binnebose,et al.  Nano-enabled delivery of diverse payloads across complex biological barriers. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[76]  F. Shieh,et al.  Imparting functionality to biocatalysts via embedding enzymes into nanoporous materials by a de novo approach: size-selective sheltering of catalase in metal-organic framework microcrystals. , 2015, Journal of the American Chemical Society.

[77]  Zhangyong Hong,et al.  Targeted Delivery of CRISPR/Cas9‐Mediated Cancer Gene Therapy via Liposome‐Templated Hydrogel Nanoparticles , 2017, Advanced functional materials.

[78]  Ping Zhu,et al.  Correction of a genetic disease by CRISPR-Cas9-mediated gene editing in mouse spermatogonial stem cells , 2014, Cell Research.

[79]  Da Xing,et al.  Graphene oxide-mediated Cas9/sgRNA delivery for efficient genome editing. , 2018, Nanoscale.

[80]  Feng Zhang,et al.  Engineered Cpf1 variants with altered PAM specificities increase genome targeting range , 2017, Nature Biotechnology.

[81]  J. Keith Joung,et al.  Improving CRISPR-Cas nuclease specificity using truncated guide RNAs , 2014, Nature Biotechnology.

[82]  Sally Lehrman,et al.  Virus treatment questioned after gene therapy death , 1999, Nature.

[83]  Zhijian Wu,et al.  Effect of genome size on AAV vector packaging. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[84]  Qiang Sun,et al.  Homology-mediated end joining-based targeted integration using CRISPR/Cas9 , 2017, Cell Research.

[85]  David R. Liu,et al.  Evolved Cas9 variants with broad PAM compatibility and high DNA specificity , 2018, Nature.

[86]  G. Lin,et al.  Potential pitfalls of CRISPR/Cas9‐mediated genome editing , 2016, The FEBS journal.

[87]  Mara Beltrán-Gastélum,et al.  Active Intracellular Delivery of a Cas9/sgRNA Complex Using Ultrasound-Propelled Nanomotors. , 2018, Angewandte Chemie.

[88]  Mary Joseph,et al.  Ocular delivery of proteins and peptides: Challenges and novel formulation approaches☆ , 2018, Advanced drug delivery reviews.

[89]  Hao Yin,et al.  Delivery technologies for genome editing , 2017, Nature Reviews Drug Discovery.

[90]  D. Carroll.  Genome Engineering With Zinc-Finger Nucleases , 2011, Genetics.

[91]  V. Torchilin.  Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery , 2014, Nature Reviews Drug Discovery.

[92]  Feng Zhang.  CRISPR-Cas9: Prospects and Challenges. , 2015, Human gene therapy.

[93]  Silke Krol,et al.  Challenges in drug delivery to the brain: nature is against us. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[94]  A. Regev,et al.  Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System , 2015, Cell.

[95]  Takanori Kanai,et al.  Modeling colorectal cancer using CRISPR-Cas9–mediated engineering of human intestinal organoids , 2015, Nature Medicine.

[96]  Y. Ikeda,et al.  Divergent susceptibilities to AAV-SaCas9-gRNA vector-mediated genome-editing in a single-cell-derived cell population , 2017, BMC Research Notes.

[97]  Chao Liang,et al.  Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma. , 2017, Biomaterials.

[98]  R. Barrangou,et al.  Applications of CRISPR technologies in research and beyond , 2016, Nature Biotechnology.

[99]  Eugene V Koonin,et al.  Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems. , 2015, Molecular cell.

[100]  Yinqing Li,et al.  Crystal Structure of Staphylococcus aureus Cas9 , 2015, Cell.

[101]  Yu-Quan Wei,et al.  Challenges in CRISPR/CAS9 Delivery: Potential Roles of Nonviral Vectors. , 2015, Human gene therapy.

[102]  Xingyu Jiang,et al.  Thermo-triggered Release of CRISPR-Cas9 System by Lipid-Encapsulated Gold Nanoparticles for Tumor Therapy. , 2018, Angewandte Chemie.

[103]  Li Zhang,et al.  Delivery strategies of the CRISPR‐Cas9 gene‐editing system for therapeutic applications , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[104]  S. Konermann,et al.  Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors , 2018, Cell.

[105]  Jae Sung Lee,et al.  Poly‐sgRNA/siRNA ribonucleoprotein nanoparticles for targeted gene disruption , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[106]  Wioletta Zielińska,et al.  Cell-penetrating peptides and their utility in genome function modifications (Review) , 2017, International journal of molecular medicine.

[107]  Zhen Gu,et al.  Macrophage-Specific in Vivo Gene Editing Using Cationic Lipid-Assisted Polymeric Nanoparticles. , 2018, ACS nano.

[108]  Hidde L Ploegh,et al.  Inhibition of non-homologous end joining increases the efficiency of CRISPR/Cas9-mediated precise [TM: inserted] genome editing , 2015, Nature Biotechnology.

[109]  J. Doudna,et al.  RNA-guided genetic silencing systems in bacteria and archaea , 2012, Nature.

[110]  Daniel J. Rader,et al.  Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing , 2014, Circulation research.

[111]  Christopher M. Vockley,et al.  RNA-guided gene activation by CRISPR-Cas9-based transcription factors , 2013, Nature Methods.

[112]  M. Shoichet,et al.  Delivery strategies for treatment of age-related ocular diseases: From a biological understanding to biomaterial solutions. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[113]  Haihua Xiao,et al.  Fluorinated Acid-Labile Branched Hydroxyl-Rich Nanosystems for Flexible and Robust Delivery of Plasmids. , 2018, Small.

[114]  Hao Yin,et al.  CRISPR-mediated direct mutation of cancer genes in the mouse liver , 2014, Nature.

[115]  M. Jinek,et al.  Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease , 2014, Nature.

[116]  D. Begley.  Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. , 2004, Pharmacology & therapeutics.

[117]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[118]  Gang Bao,et al.  CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery. , 2017, Chemical reviews.

[119]  Gérard Férey,et al.  Metal-organic frameworks in biomedicine. , 2012, Chemical reviews.

[120]  J. Joung,et al.  Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition , 2015, Nature Biotechnology.

[121]  Qiang Zhang,et al.  Surface-engineered dendrimers in gene delivery. , 2015, Chemical reviews.

[122]  Kira S. Makarova,et al.  Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems , 2013, Nucleic acids research.

[123]  Daniel G. Anderson,et al.  Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.

[124]  Jennifer A. Doudna,et al.  New CRISPR-Cas systems from uncultivated microbes , 2016, Nature.

[125]  J. Doudna,et al.  The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[126]  Yizhou Dong,et al.  Design and assessment of engineered CRISPR–Cpf1 and its use for genome editing , 2018, Nature Protocols.

[127]  Kang Liang,et al.  Metal-Organic Frameworks at the Biointerface: Synthetic Strategies and Applications. , 2017, Accounts of chemical research.

[128]  Suresh Ramakrishna,et al.  Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA , 2014, Genome research.

[129]  Simona Valletta,et al.  Application of CRISPR/Cas9 genome editing to the study and treatment of disease , 2015, Archives of Toxicology.

[130]  E. Rebar,et al.  Genome editing with engineered zinc finger nucleases , 2010, Nature Reviews Genetics.

[131]  Morgan L. Maeder,et al.  Genome-editing Technologies for Gene and Cell Therapy , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[132]  Yonghao Yu,et al.  The LC Domain of hnRNPA2 Adopts Similar Conformations in Hydrogel Polymers, Liquid-like Droplets, and Nuclei , 2015, Cell.

[133]  Namritha Ravinder,et al.  Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. , 2015, Journal of biotechnology.

[134]  Alec N. Salt,et al.  Communication pathways to and from the inner ear and their contributions to drug delivery , 2017, Hearing Research.

[135]  Chia-Yang Liu,et al.  Electrically assisted delivery of macromolecules into the corneal epithelium. , 2009, Experimental eye research.

[136]  Won-Bin Young,et al.  In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[137]  Yu Wang,et al.  Fluorinated poly(propylenimine) dendrimers as gene vectors. , 2014, Biomaterials.

[138]  David J Mooney,et al.  Sustained delivery of plasmid DNA from polymeric scaffolds for tissue engineering. , 2006, Advanced drug delivery reviews.

[139]  David A. Scott,et al.  In vivo genome editing using Staphylococcus aureus Cas9 , 2015, Nature.